ISO 80369 Small-Bore Connector Conversion: 510(k), FDA Windows & Particular Parts

Manufacturer ISO 80369 conversion guide: route-specific particular parts, FDA recognition transition windows through Dec 17, 2028, and 510(k) change forks.

For medical device manufacturers producing infusion systems, enteral feeding tubes, neuraxial anesthesia sets, respiratory circuits, and blood pressure cuffs, converting legacy Luer or proprietary fittings to the ISO 80369 series of small-bore connectors is a complex regulatory, engineering, and supply-chain undertaking.

While clinical advocacy groups and hospital procurement teams emphasize wrong-route misconnection risks, regulatory affairs (RA) and quality engineering leaders face rigorous design control and premarket submission gates. Device manufacturers must navigate exact FDA recognized consensus standard transition dates, understand why declaring conformity to ISO 80369-1 does not satisfy route-specific dimensional requirements, resolve discrepancies between FDA education portals and official recognition databases, and determine when a connector change triggers a new 510(k) premarket notification under Food and Drug Administration (FDA) change-control guidance.

The Core Direct Answer: The ISO 80369 standard series is a multi-part family governed by an overarching architecture: ISO 80369-1 establishes general performance requirements and non-interconnectable design principles, but each distinct clinical route is governed by a particular part that defines non-interconnectable physical geometry and dimensions.

In the United States, FDA recognizes the ISO 80369 family with specific, time-bound transition windows:

ISO 80369-1 (General Requirements): Recognized under FDA Rec# 5-147 (Third Edition 2025-10); declarations of conformity to the second edition 2018 (Rec# 5-121) remain acceptable in premarket submissions until December 17, 2028.

ISO 80369-6 (Neuraxial / NRFit): Recognized under FDA Rec# 5-146 (Second Edition 2025-05); declarations of conformity to the first edition 2016 (Rec# 5-108) remain acceptable until December 17, 2028.

ISO 80369-3 (Enteral / ENFit): Recognized under FDA Rec# 5-123 (ISO 80369-3:2016 + Amendment 1:2019), active with date of entry July 15, 2019.

ISO 80369-7 (Intravascular / Hypodermic): Recognized under FDA Rec# 5-133 (Second Edition 2021-05). FDA's Date of Entry on that record is December 21, 2020—the database field, not the ISO publication date. (The same FDA connectors education page still describing ISO 80369-7:2021 as "being finalized" lags the recognition database; Rec# 5-133 is the legal authority.)

ISO 80369-2 (Breathing Systems): Recognized under FDA Rec# 1-195 (First Edition 2024-09), date of entry May 26, 2025.

IEC 80369-5 (Limb Cuff): Recognized under FDA Rec# 5-107 (First Edition 2016, including Corrigenda 1 (2017) and 2 (2021)); FDA Date of Entry August 21, 2017.

ISO 80369-20 (Common Test Methods): Recognized under FDA Rec# 5-144 (Second Edition 2024-11); declarations of conformity to the first edition 2015 (Rec# 5-97) remain acceptable until July 2, 2028.

Urinary Applications: There is no published ISO 80369-4 urinary particular part in the recognized consensus standard family; manufacturers must not invent an "ENFit-style Foley conversion."

On September 7, 2018, FDA issued a formal safety letter to hospital purchasers and manufacturers citing passive surveillance reports since 2011 involving 2 deaths, 24 serious injuries, and 32 device malfunctions related to enteral misconnections. That letter recommended specifying ISO 80369-1 or ISO 80369-3 in purchasing; however, this is purchasing advice, not a regulatory exemption to skip particular-part geometry. The February 2015 FDA guidance announced in Federal Register notice FR 2015-02802 (80 FR 7619) rejects color-coding, labeling, or physical tagging alone as an adequate risk control for small-bore misconnections. Finally, under FDA's "Deciding When to Submit a 510(k) for a Change to an Existing Device" guidance, converting an existing cleared device to ISO 80369 requires evaluating fluid dynamics, material biocompatibility, and user-interface changes to determine whether a new 510(k) or an internal Letter-to-File applies.

Status Summary: The Complete ISO 80369 Recognized Standard Matrix

The following table summarizes the ISO 80369 family structure, clinical routes, FDA Recognized Consensus Standard numbers, and active transition windows:

Clinical Route & Part	Standard Title & Edition	FDA Recognition Number	Premarket Transition Deadline	Clinical Application Scope
General Requirements	ISO 80369-1:2025 (3rd Ed.)	Rec# 5-147	December 17, 2028 (DoC to 2018 Rec# 5-121 accepted until this date)	Framework, non-interconnectable methodology, common test methods.
Breathing Systems & Driving Gases	ISO 80369-2:2024 (1st Ed.)	Rec# 1-195	Date of entry May 26, 2025; active standard	Ventilator circuits, nebulizers, anesthesia gas lines, respiratory humidification.
Enteral Applications (ENFit)	ISO 80369-3:2016 + A1:2019	Rec# 5-123	Active standard (Date of entry July 15, 2019)	Nasogastric tubes, PEG tubes, enteral feeding sets, enteral syringes.
Urethral / Urinary	ISO 80369-4 (Unpublished / Withdrawn)	None (No Recognition Record)	N/A — No recognized standard	Foley catheters, drainage bags (maintain existing clinical connection standards).
Limb Cuff Inflation	IEC 80369-5:2016 (1st Ed.)	Rec# 5-107	Active standard (Date of entry August 21, 2017)	Non-invasive blood pressure (NIBP) cuffs, pneumatic tourniquets.
Neuraxial & Anesthesia (NRFit)	ISO 80369-6:2025 (2nd Ed.)	Rec# 5-146	December 17, 2028 (DoC to 2016 Rec# 5-108 accepted until this date)	Epidural catheters, spinal needles, regional anesthesia blocks, LP manometers.
Intravascular & Hypodermic	ISO 80369-7:2021 (2nd Ed.)	Rec# 5-133	Active standard (FDA Date of Entry December 21, 2020; ISO edition dated 2021-05)	IV administration sets, hypodermic syringes, vascular access devices (Luer lock/slip).
Common Test Methods	ISO 80369-20:2024 (2nd Ed.)	Rec# 5-144	July 2, 2028 (DoC to 2015 Rec# 5-97 accepted until this date)	Standardized physical test methods for dimensional, leakage, stress cracking, and separation.

Which ISO 80369 Particular Part Applies to Which Clinical Route?

A foundational error in medical device design controls is treating small-bore connector conversion as a single generic standard. The ISO 80369 series was deliberately engineered with mutually exclusive geometric profiles to make physical cross-connection between incompatible clinical delivery lines physically impossible.

Particular part	Clinical route	Typical commercial name
ISO 80369-1	General requirements and non-interconnectability methodology—not a substitute for a particular-part geometry	—
ISO 80369-2	Breathing systems and driving gases	—
ISO 80369-3	Enteral	ENFit
ISO 80369-4	Urinary / urethral	No published, FDA-recognized particular part—do not invent one
IEC 80369-5	Limb-cuff inflation (NIBP)	—
ISO 80369-6	Neuraxial	NRFit
ISO 80369-7	Intravascular / hypodermic	Luer (updated 80369-7 geometry)

Route-Specific Analysis

Enteral Systems (ISO 80369-3 / ENFit): Enteral nutrition delivery systems historically utilized standard Luer fittings, resulting in fatal clinical events where enteral formula was inadvertently connected to intravenous access lines. ISO 80369-3 defines the locking ENFit geometry, reversing standard gender orientations (the feeding tube administration port has female locking threads with a male bore) to prevent connection to Luer syringes or IV access ports.
Neuraxial Systems (ISO 80369-6 / NRFit): Designed for local and regional anesthesia, spinal access, and epidural infusions. NRFit uses a distinct non-interconnectable geometry versus Luer so neuraxial lines cannot mate with IV Luer, enteral, or NIBP cuff connectors. Confirm exact dimensions in the purchased particular part.
Intravascular & Hypodermic (ISO 80369-7 / Luer): Retains the traditional 6% taper Luer connector geometry for vascular access and hypodermic injections. Converting an IV administration line to ISO 80369-7 involves updating technical files and inspection protocols from legacy ISO 594-1/ISO 594-2 to ISO 80369-7:2021.
Breathing & Gas Systems (ISO 80369-2): Establishes dedicated connectors for respiratory driving gases, nebulizers, and oxygen delivery sub-lines to prevent misconnection to liquid infusion or enteral lines.
Limb Cuffs (IEC 80369-5): Defines specialized bayonet and push-fit connectors for NIBP monitoring cuffs, ensuring blood pressure tubing cannot be connected to IV lines or neuraxial blocks.

In commercial hospital tenders and biomedical procurement, understanding hospital route-first connector selection helps manufacturers align packaging, SKU transitions, and clinical education materials with hospital value analysis committees.

Does ISO 80369-1 Replace the Particular-Part Geometry Test?

A critical compliance misconception is assuming that a Declaration of Conformity to ISO 80369-1 satisfies the technical file requirements for a finished device.

Claim	FDA / technical-file result
"Device complies with ISO 80369-1:2025" alone on an enteral, neuraxial, IV, breathing, or limb-cuff product	Insufficient. Part 1 is the general methodology; it does not publish the particular-part dimensional profile.
Declare the matching particular part (80369-3 / -6 / -7 / -2 or IEC 80369-5) plus ISO 80369-20 common tests	This is the recognition-family pattern reviewers expect.

The Role of Part 1 vs. Particular Parts

ISO 80369-1 (Small-bore connectors for liquids and gases in healthcare applications — Part 1: General requirements) establishes the mathematical and physical methodology used by standards committees to evaluate whether proposed connector profiles can physically mate. It includes:

General performance requirements for small-bore connectors.
Risk management criteria for misconnections.
Assessment frameworks for novel connector geometries.

However, ISO 80369-1 does not contain the engineering drawings, dimensional tables, or fluid leak test limits for specific clinical lines. To clear an enteral feeding set, an FDA 510(k) submission or EU MDR Technical File under harmonised standards must provide physical test data confirming dimensional compliance to ISO 80369-3, accompanied by testing performed in accordance with ISO 80369-20 (Common test methods) for fluid leakage, sub-atmospheric pressure air leakage, stress cracking, axial load separation, and unscrewing torque.

Which FDA Recognition Editions Remain Valid Until December 17, 2028?

When FDA updates its Recognized Consensus Standards database, it publishes specific transition windows during which declarations of conformity to older standard editions remain legally acceptable.

Standard	Current recognition	Older edition still accepted in a DoC until
ISO 80369-1	Rec# 5-147 (3rd ed. 2025-10); FDA Date of Entry December 22, 2025	Rec# 5-121 (2018) until December 17, 2028
ISO 80369-6	Rec# 5-146 (2nd ed. 2025-05); FDA Date of Entry December 22, 2025	Rec# 5-108 (2016) until December 17, 2028
ISO 80369-20	Rec# 5-144 (2nd ed. 2024-11); FDA Date of Entry May 26, 2025	Rec# 5-97 (2015) until July 2, 2028

Key Active Transition Dates

ISO 80369-1 (Part 1): FDA recognized the third edition (ISO 80369-1:2025-10) under Recognition Number 5-147. The FDA recognition record explicitly states that declarations of conformity to the second edition (ISO 80369-1:2018, formerly recognized under Rec# 5-121) will remain acceptable in regulatory submissions until December 17, 2028.
ISO 80369-6 (Neuraxial / NRFit): FDA recognized the second edition (ISO 80369-6:2025-05) under Recognition Number 5-146. The transition period permits sponsors to submit declarations of conformity to the first edition (ISO 80369-6:2016, Rec# 5-108) until December 17, 2028.
Resolving education-page lag: On FDA's "Reducing Risks through Standards Development for Medical Device Connectors" page, ISO 80369-7:2021 is still described as "being finalized," and breathing-system work is still described as underway. The recognition database is the legal authority: Rec# 5-133 already lists ISO 80369-7 Second edition 2021-05 (FDA Date of Entry December 21, 2020), and Rec# 1-195 already lists ISO 80369-2 First edition 2024-09 (Date of Entry May 26, 2025).

When Does a Connector Conversion Require a New 510(k) Instead of a Letter to File?

When modifying an existing commercial device from a legacy connector (e.g., Luer) to an ISO 80369 connector (e.g., ENFit or NRFit), manufacturers must evaluate the change under FDA's final guidance Deciding When to Submit a 510(k) for a Change to an Existing Device.

Change question	If yes	If no
Did the resin, plasticizer, or contact material change category?	Plan ISO 10993 biological evaluation; the 510(k) vs letter-to-file outcome still depends on whether the change could significantly affect safety or effectiveness.	Continue to flow, labeling, and human-factors questions.
Did lumen geometry, gravity flow, or pump-pressure behavior change in a way that could affect labeled performance?	A new 510(k) is more likely. There is no official FDA "20% flow" numeric trigger—document comparative flow/pressure data and apply the 2017 change-control guidance.	Evaluate labeling, IFU, and human factors.
Does the change introduce a new risk or alter the labeled route of administration?	New 510(k).	Document a letter-to-file in the DHF/DMR if the remaining analysis supports it.

510(k) Decision Logic Matrix for Connector Changes

Change Parameter	Risk & Regulatory Analysis	Regulatory Pathway	Documentation Required
Drop-in Standard Replacement (Same Material, Identical Flow)	Sourcing an off-the-shelf molded ISO 80369 connector using identical medical-grade polycarbonate/polypropylene; flow rate and pressure drops verified equivalent.	Letter to File (Internal Change Memo)	Updated DMR, drawing revisions, ISO 80369-20 dimensional and leak test data, risk assessment under change control.
Material Formulation Change (New Resin or Plasticizer)	Supplier changes connector material from rigid PVC to a new copolyester or TPE formulation to accommodate welding.	510(k) Evaluation (Depends on Biocompatibility & Chemical Characterization)	ISO 10993 biological evaluation, cytotoxicity, extractables/leachables, aging stability data.
Significant flow or pressure change (high-viscosity feeds or gravity)	Transitioning to a connector that changes internal diameter, gravity flow, or pump pressure enough to affect labeled performance.	510(k) more likely (no official FDA percent-flow cutoff)	Comparative bench testing, fluid-delivery characterization, flow vs. pressure curves, software alarm limits.
New Indication or Labeled Route Change	Adding an NRFit connector to expand an existing surgical catheter into regional continuous nerve blocks.	New 510(k) Required	Clinical rationale, human factors validation, labeling overhaul, sterilization re-validation.
Transition Adapter Inclusion (Temporary Co-Packaging)	Packaging a temporary Luer-to-ENFit transition adapter in the primary sterile pouch to bridge hospital transition.	Letter to File or 510(k) (Dependent on adapter clearance status)	If adapter is already 510(k)-cleared as an accessory: Letter to File. If novel adapter: 510(k).

When managing single-use catalog components, quality teams must ensure that off-the-shelf component qualifications and tubing extrusion supplier validations maintain strict dimensional control across the mating bond interface.

Why Is FDA's 2018 "80369-1 or 80369-3" Sentence Not a Design Exemption?

On September 7, 2018, FDA CDRH issued a letter to manufacturers, health care professionals, and hospital purchasing departments titled Letter to Manufacturers, Health Care Professionals, and Hospital Purchasing Departments.

The Passive Surveillance Data

In the 2018 safety communication, FDA published passive surveillance data from its Manufacturer and User Facility Device Experience (MAUDE) database:

"Since 2011, the FDA has received reports of 2 deaths, 24 serious injuries, and 32 device malfunctions related to enteral misconnections." (FDA CDRH Safety Letter, September 7, 2018).

As an evidence-based regulatory analysis, it is essential to emphasize that passive surveillance report counts do not equal population incidence or prove direct epidemiological causality. However, these reports formed the regulatory catalyst for CDRH's recommendation that healthcare facilities accelerate the transition to misconnection-resistant designs.

Deconstructing the "80369-1 or 80369-3" Phrasing

The letter stated that hospital purchasing departments should specify connectors complying with "ISO 80369-1 or ISO 80369-3."

Some commercial teams misinterpreted this sentence as a legal loophole, arguing that a manufacturer could declare compliance with ISO 80369-1 (General requirements) while continuing to ship legacy Luer fittings on enteral lines.

This interpretation is false:

Purchasing Context: The phrase "ISO 80369-1 or ISO 80369-3" was directed at hospital procurement departments writing Request for Proposals (RFPs), allowing hospitals to contract for misconnection-resistant systems broadly.
Design Standard Requirements: For medical device manufacturers submitting premarket files to FDA under 21 CFR § 807, FDA premarket reviewers require conformity to the specific particular part (ISO 80369-3 for enteral). Citing Part 1 while retaining a legacy Luer geometry fails CDRH review.
FDA Letter Instructions: The 2018 letter explicitly instructed healthcare providers to:
- Minimize the use of temporary transition adapters.
- Never force connections or modify fittings to make them mate.
- Transition to dedicated enteral connectors to eliminate cross-talk with vascular lines.

What Fails If You Treat Color-Coding as the Misconnection Control?

In earlier decades, device manufacturers attempted to mitigate wrong-route administration risks by applying colored plastics—such as orange or purple enteral lines, or yellow neuraxial tubing—or attaching warning tags stating "ENTERAL USE ONLY."

Control	Standing
Color-coded plastics, "not for IV" labels, adhesive tags	Not sufficient alone. FDA's connectors education page states that color-coding, labels, tags, and training have not physically prevented misconnections. The 2015 enteral-connector guidance (announced at 80 FR 7619, document 2015-02802) makes the same point.
ISO 80369 particular-part geometry	The engineered physical incompatibility the standards family is built around.

The 2015 guidance is not a regulation

On February 11, 2015, FDA announced availability of Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications (80 FR 7619, document 2015-02802). That Federal Register document is a guidance-availability notice, not a codified rule.

The guidance and FDA's connectors education page both treat color, labeling, and tagging as inadequate by themselves. Physical, geometric incompatibility under the applicable ISO 80369 particular part is the design control manufacturers should plan around.

What Does Conversion Cost: Standards, Testing, Inventory, and MDUFA versus No Connector User Fee?

Budgeting an ISO 80369 conversion requires separating internal development costs from government regulatory fees.

Cost category	What it is	Source basis
Government user fees	$0 FDA or CMS "80369 conversion" fee. Standard MDUFA applies only if the change requires a new 510(k).	No conversion fee schedule; MDUFA is a premarket-submission fee.
Standards purchase	Official ISO/IEC 80369 parts must be purchased. List prices vary by part and vendor.	ISO/IEC webstore; not a government fee.
Tooling, ISO 80369-20 testing, ISO 10993 (if resin changes), dual inventory	Internal or provider costs. Published dollar ranges are MedDeviceGuide estimates, not quotes.	Internal estimate.

Cost Categories Explained

Government Fees ($0 Base): There is no FDA user fee for converting to ISO 80369. The only government fee that may apply is the standard FDA MDUFA user fee if the modification requires a new 510(k) submission. If the change qualifies for an internal Letter-to-File, federal filing costs are $0.
Standards Acquisition: Standards must be purchased from ISO or national standards organizations (ANSI, DIN, BSI). Confirm current list prices on the official webstore; do not treat a blog range as an ISO tariff.
Mechanical Testing (ISO 80369-20): Validating a connector requires executing the physical test battery in the purchased ISO 80369-20 text (dimensional checks, positive-pressure liquid leakage, sub-atmospheric air leakage, stress cracking, axial separation, and torque). Do not copy numeric pass/fail rows from secondary blogs; use the edition you declare.
Dual Inventory and Transition Management: During market conversion, manufacturers must maintain dual SKUs (legacy Luer and new ISO 80369) to support hospital accounts transitioning at varying speeds, carrying temporary inventory holding costs.

ISO 80369 30/60/90-Day Manufacturer Conversion Plan

Medical device manufacturers planning an ISO 80369 connector transition should execute the following 90-day engineering and regulatory plan:

Window	Focus	First actions
Days 1–30	Portfolio and pathway	Map SKUs to particular parts; run the 2017 510(k)-change guidance; re-verify Rec# 5-147, 5-146, 5-133, 5-144, and 1-195.
Days 31–60	Tooling and bench	Qualify molded or catalog connectors; run the purchased ISO 80369-20 battery; compare flow against the labeled performance.
Days 61–90	File and launch	Sign letters-to-file or assemble 510(k)s; release labeling/IFU; stock dual-SKU buffers.

Phase 1: Days 1–30 — Portfolio Mapping & Regulatory Screening

SKU Inventory Audit: Identify all single-use and reusable device lines currently utilizing small-bore connectors. Map each product line to its mandatory particular part (Enteral → Part 3; Neuraxial → Part 6; IV → Part 7; Breathing → Part 2; NIBP → Part 5).
Regulatory Pathway Determination: Apply FDA’s Deciding When to Submit a 510(k) for a Change to an Existing Device guidance. Document whether each conversion represents a Letter-to-File or requires a new 510(k).
Recognition Window Confirmation: Verify that premarket submissions reference current FDA Recognized Consensus Standards and plan transitions before the December 17, 2028 cut-off for older Part 1 and Part 6 editions.

Phase 2: Days 31–60 — Sourcing, Tooling & Verification

Supplier Quality Agreements: Audit connector component suppliers under ISO 13485 purchasing controls. Ensure component vendors provide certified dimensional inspection reports against ISO 80369 particular part drawings.
ISO 80369-20 Testing: Contract or perform in-house physical testing covering positive pressure liquid leakage, sub-atmospheric air leakage, stress cracking, axial separation force, and torque resistance.
Flow Rate Verification: Conduct comparative flow rate testing comparing legacy Luer flow curves against the new connector profile to prove clinical equivalence.

Phase 3: Days 61–90 — Regulatory Closure & Market Rollout

DHF & DMR Updates: Finalize Design History File updates, risk management file revisions under ISO 14971, and Device Master Record drawings.
Submission / Memo Filing: Submit 510(k) applications to FDA CDRH or complete and sign internal Letter-to-File justification memos.
Labeling & Artwork Release: Release updated sterile pouch artwork, carton labels, and IFU documents clearly highlighting the new connector standard and preventing customer connection confusion.

Frequently Asked Questions

Can we declare ISO 80369-1 and keep a Luer geometry on an enteral line?

No. ISO 80369-1 establishes general requirements and non-interconnectability frameworks, but does not define route-specific geometry. For enteral applications, FDA and global regulators require conformity to the particular part, ISO 80369-3 (ENFit). Retaining a Luer fitting on an enteral device violates CDRH safety expectations and will result in premarket submission deficiencies.

Until when may we still declare ISO 80369-1:2018 or ISO 80369-6:2016 in a 510(k) DoC?

Until December 17, 2028 for Parts 1 and 6. Under FDA Recognition Numbers 5-147 (Part 1) and 5-146 (Part 6), FDA will accept declarations of conformity to ISO 80369-1:2018 (Rec# 5-121) and ISO 80369-6:2016 (Rec# 5-108) in premarket submissions until December 17, 2028. Separately, Rec# 5-144 accepts DoCs to ISO 80369-20:2015 (Rec# 5-97) until July 2, 2028.

Does FDA still consider ISO 80369-7:2021 "being finalized"?

No. Although FDA's consumer-facing education portal has lagged in updating its informational text, the official FDA Recognized Consensus Standards database has formally recognized ISO 80369-7:2021 (Second Edition) under Recognition Number 5-133 since December 21, 2020. Manufacturers should reference Rec# 5-133 in their premarket declarations of conformity.

Is there an ISO 80369-4 urinary connector we must convert Foley catheters to?

No. There is currently no published or recognized ISO 80369-4 particular part for urethral/urinary applications. Manufacturers of urinary drainage bags, Foley catheters, and irrigation sets should maintain existing recognized catheter standards and must not invent non-standard fittings claiming compliance with ISO 80369-4.

Does the 2018 FDA letter require hospitals to buy ENFit, or manufacturers to ship ENFit?

The 2018 FDA letter is purchasing guidance, not a statute. It recommended that hospital purchasing departments specify ISO 80369-1 or ISO 80369-3 compliant systems in tenders to reduce misconnection risks. For manufacturers, the expectation of misconnection-resistant designs comes from premarket review, the 2015 enteral-connector guidance announced at 80 FR 7619 (document 2015-02802), and risk-management obligations under ISO 14971 / 21 CFR Part 820.

Is there an FDA or CMS fee for ISO 80369 conversion itself?

There is no government conversion fee. FDA and CMS do not charge user fees to adopt standard connector geometries. Standard MDUFA user fees apply only if the modification requires a new 510(k) premarket notification. Standards purchases, tooling, laboratory testing, and inventory scrap are internal commercial costs.

How Pure Global Supports Small-Bore Connector Conversions and 510(k) Filings

Successfully transitioning a medical device line to ISO 80369 requires coordinated execution across design controls, recognized consensus standards testing, and FDA change-control regulatory filings.

Pure Global provides comprehensive regulatory consulting, 510(k) submission preparation, and quality system engineering for global medical technology manufacturers.

Our specialized regulatory and testing practices assist medical device companies with:

510(k) Premarket Submissions & Change Analysis: Authoring 510(k) notifications and Letter-to-File justifications for connector conversions through our dedicated 510(k) Submission Services team.
US FDA Market Access & Regulatory Strategy: Navigating FDA recognized consensus standards, premarket transition windows, and CDRH review policies via our United States Market Access advisory practice.
Quality Management System & Design Controls: Updating Design History Files, Device Master Records, and supplier controls to comply with ISO 13485:2016 and FDA QMSR (21 CFR Part 820).
Global Compliance (EU MDR & International): Ensuring technical documentation aligns with EU MDR Annex II/III general safety and performance requirements (GSPR) for connector non-interconnectability.

To review your small-bore connector conversion strategy, 510(k) change documentation, or global regulatory technical files, contact Pure Global.

Pure Global provides independent regulatory and compliance consulting services. Pure Global is not the Food and Drug Administration (FDA), the International Organization for Standardization (ISO), a European Notified Body, or the Global Enteral Device Supplier Association (GEDSA).

Sources

FDA Recognized Consensus Standards: ISO 80369-1:2025 (Rec# 5-147) — U.S. Food and Drug Administration (standard dated 2025-10; FDA Date of Entry December 22, 2025; DoC to Rec# 5-121 accepted until December 17, 2028).
FDA Recognized Consensus Standards: ISO 80369-6:2025 (Rec# 5-146) — U.S. Food and Drug Administration (standard dated 2025-05; FDA Date of Entry December 22, 2025; DoC to Rec# 5-108 accepted until December 17, 2028).
FDA Recognized Consensus Standards: ISO 80369-3:2016+A1:2019 (Rec# 5-123) — U.S. Food and Drug Administration (Date of Entry July 15, 2019).
FDA Recognized Consensus Standards: ISO 80369-7:2021 (Rec# 5-133) — U.S. Food and Drug Administration (ISO edition 2021-05; FDA Date of Entry December 21, 2020).
FDA Recognized Consensus Standards: ISO 80369-2:2024 (Rec# 1-195) — U.S. Food and Drug Administration (Date of Entry May 26, 2025).
FDA Recognized Consensus Standards: IEC 80369-5:2016 (Rec# 5-107) — U.S. Food and Drug Administration (Date of Entry August 21, 2017; including Corrigenda 1 (2017) and 2 (2021)).
FDA Recognized Consensus Standards: ISO 80369-20:2024 (Rec# 5-144) — U.S. Food and Drug Administration (Date of Entry May 26, 2025; DoC to Rec# 5-97 accepted until July 2, 2028).
Letter to Manufacturers, Health Care Professionals, and Hospital Purchasing Departments (September 7, 2018) — U.S. Food and Drug Administration (CDRH).
Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications; Guidance Availability — Food and Drug Administration / Federal Register (80 FR 7619, document 2015-02802; February 11, 2015).
Deciding When to Submit a 510(k) for a Change to an Existing Device — U.S. Food and Drug Administration (Final Guidance, October 2017).
Medical Device Connectors - Reducing Risks through Standards Development — U.S. Food and Drug Administration.